Ignite Creation Date:
2024-10-26 @ 3:42 PM
Last Modification Date:
2024-10-26 @ 3:42 PM
Study NCT ID:
NCT06641453
Status:
NOT_YET_RECRUITING
Last Update Posted:
None
First Post:
2024-10-12
Brief Title:
CAR-T Cell Therapy Targeting GPC3 in Patients with Advanced GPC3-Positive Hepatocellular Carcinoma
Sponsor:
None
Organization:
None
Study Overview
Official Title:
Phase III Study of CAR-T Cell Therapy Targeting GPC3 in Patients with Treated Advanced GPC3-Positive Hepatocellular Carcinoma
Status:
NOT_YET_RECRUITING
Status Verified Date:
2024-10
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
No
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
In this single-center single-arm prospective open-label Phase 12 study the safety and efficacy of autologous GPC3-targeted chimeric antigen receptor CAR T-cell therapy will be evaluated in patients with GPC3-positive advanced hepatocellular carcinoma
Phase 1 will involve the enrollment of six eligible patients to receive hepatic arterial infusion of GPC3-CAR T cells at a fixed dose of 1106 cellskg with or without a standard lymphodepleting conditioning regimen fludarabine and cyclophosphamide Based on the results it will be assessed whether the FC lymphodepletion regimen is necessary Subsequently an additional six patients will be enrolled in a 33 dose-escalation design to adjust the dose of GPC3-CAR T cells to achieve optimal safety and efficacy The recommended Phase 2 dose RP2D will then be established
Phase 2 will involve the enrollment of 10-20 additional eligible patients to receive GPC3-CAR T cell therapy at the RP2D
Phase 1 will involve the enrollment of six eligible patients to receive hepatic arterial infusion of GPC3-CAR T cells at a fixed dose of 1106 cellskg with or without a standard lymphodepleting conditioning regimen fludarabine and cyclophosphamide Based on the results it will be assessed whether the FC lymphodepletion regimen is necessary Subsequently an additional six patients will be enrolled in a 33 dose-escalation design to adjust the dose of GPC3-CAR T cells to achieve optimal safety and efficacy The recommended Phase 2 dose RP2D will then be established
Phase 2 will involve the enrollment of 10-20 additional eligible patients to receive GPC3-CAR T cell therapy at the RP2D
Detailed Description:
Glypican-3 GPC3 is a member of the glypican family a group of heparan sulfate proteoglycans that are anchored to the cell membrane via a glycosylphosphatidylinositol GPI linkage Structurally GPC3 is composed of a core protein and covalently attached heparan sulfate chains The core protein consists of an N-terminal domain a large cysteine-rich region and a C-terminal region that interacts with the cell membrane Functionally GPC3 is involved in regulating cell growth differentiation and apoptosis through interactions with various growth factors including Wnt Hedgehog and fibroblast growth factors FGFs GPC3 plays a critical role during embryonic development but is largely absent in most adult tissues However its re-expression in certain cancers particularly hepatocellular carcinoma HCC makes it an attractive target for therapeutic intervention
GPC3 is highly and specifically expressed in hepatocellular carcinoma a common form of primary liver cancer while being minimally expressed in normal adult liver tissues This differential expression makes GPC3 an appealing and specific target for cancer therapyIn HCC GPC3 has been shown to play a role in promoting tumor growth and angiogenesis enhancing tumor invasiveness and protecting cancer cells from apoptosis Due to its overexpression in HCC tumor tissues GPC3 has been widely recognized as a potential biomarker for diagnosis prognosis and targeted therapies Its selective expression in cancerous tissue with limited distribution in normal tissues makes it an ideal candidate for chimeric antigen receptor CAR T cell therapy which aims to specifically target and destroy cancer cells while minimizing off-target effects
Several studies have explored the use of GPC3-targeted CAR T cell therapies in hepatocellular carcinoma These early clinical trials were designed to evaluate the safety and preliminary efficacy of GPC3-CAR T cell treatments in patients with advanced-stage GPC3-positive HCC The results from these trials demonstrated that GPC3-CAR T cell therapy is generally safe with manageable adverse effects and some patients exhibited clinical responses such as tumor regression or disease stabilization However despite these promising results the overall efficacy of GPC3-CAR T cell therapy did not meet the threshold required for routine clinical application The responses were often transient and relapse occurred in many patients due to challenges such as T cell exhaustion limited CAR T cell persistence and the immunosuppressive tumor microenvironment TME associated with HCC These limitations highlighted the need for further optimization of the CAR T cell design and administration strategies to improve the efficiency of GPC3-targeted therapies in HCC
Building on the foundation of these earlier studies the investigators aim to conduct a prospective open-label phase 12 clinical trial to evaluate our newly optimized GPC3-targeted CAR T cell therapy in patients with advanced-stage GPC3-positive HCC Our approach introduces two major innovations compared to previous studies
1 Novel CAR T Cell Design Strategy In addition to the traditional CAR structure comprising a single-chain variable fragment scFv specific for GPC3 a co-stimulatory domain 41BBCD28 and a CD3ΞΆ activation domain we have incorporated novel immune microenvironment-activating elements These elements are designed to enhance the activation and proliferation of CAR T cells while simultaneously recruiting and activating antigen-presenting cells APCs and bystander immune effector cells This dual activation strategy aims to overcome the immunosuppressive TME and promote a more robust and sustained anti-tumor response
2 New Administration Route Unlike previous studies that primarily used intravenous administration the investigators have developed a new method of delivering CAR T cells directly into the tumor site This strategy is intended to facilitate immediate and direct contact between the CAR T cells and the tumor cells allowing for more efficient tumor infiltration and modification of the TME By altering the local immune landscape the investigators aim to enhance CAR T cell persistence and efficacy while reducing the likelihood of tumor escape
By leveraging these two innovative strategies the investigators aim to achieve improved clinical outcomes in terms of both safety and efficacy The investigators hypothesize that the inclusion of immune microenvironment-activating elements will enhance the activation of not only CAR T cells but also the broader immune system creating a more hostile environment for tumor cells Furthermore direct tumor delivery of CAR T cells may increase their local concentration and activity reducing the tumor burden more effectively Through this optimized approach the investigators hope to provide a more potent and durable therapeutic option for patients with GPC3-positive hepatocellular carcinoma addressing the limitations encountered in previous trials
GPC3 is highly and specifically expressed in hepatocellular carcinoma a common form of primary liver cancer while being minimally expressed in normal adult liver tissues This differential expression makes GPC3 an appealing and specific target for cancer therapyIn HCC GPC3 has been shown to play a role in promoting tumor growth and angiogenesis enhancing tumor invasiveness and protecting cancer cells from apoptosis Due to its overexpression in HCC tumor tissues GPC3 has been widely recognized as a potential biomarker for diagnosis prognosis and targeted therapies Its selective expression in cancerous tissue with limited distribution in normal tissues makes it an ideal candidate for chimeric antigen receptor CAR T cell therapy which aims to specifically target and destroy cancer cells while minimizing off-target effects
Several studies have explored the use of GPC3-targeted CAR T cell therapies in hepatocellular carcinoma These early clinical trials were designed to evaluate the safety and preliminary efficacy of GPC3-CAR T cell treatments in patients with advanced-stage GPC3-positive HCC The results from these trials demonstrated that GPC3-CAR T cell therapy is generally safe with manageable adverse effects and some patients exhibited clinical responses such as tumor regression or disease stabilization However despite these promising results the overall efficacy of GPC3-CAR T cell therapy did not meet the threshold required for routine clinical application The responses were often transient and relapse occurred in many patients due to challenges such as T cell exhaustion limited CAR T cell persistence and the immunosuppressive tumor microenvironment TME associated with HCC These limitations highlighted the need for further optimization of the CAR T cell design and administration strategies to improve the efficiency of GPC3-targeted therapies in HCC
Building on the foundation of these earlier studies the investigators aim to conduct a prospective open-label phase 12 clinical trial to evaluate our newly optimized GPC3-targeted CAR T cell therapy in patients with advanced-stage GPC3-positive HCC Our approach introduces two major innovations compared to previous studies
1 Novel CAR T Cell Design Strategy In addition to the traditional CAR structure comprising a single-chain variable fragment scFv specific for GPC3 a co-stimulatory domain 41BBCD28 and a CD3ΞΆ activation domain we have incorporated novel immune microenvironment-activating elements These elements are designed to enhance the activation and proliferation of CAR T cells while simultaneously recruiting and activating antigen-presenting cells APCs and bystander immune effector cells This dual activation strategy aims to overcome the immunosuppressive TME and promote a more robust and sustained anti-tumor response
2 New Administration Route Unlike previous studies that primarily used intravenous administration the investigators have developed a new method of delivering CAR T cells directly into the tumor site This strategy is intended to facilitate immediate and direct contact between the CAR T cells and the tumor cells allowing for more efficient tumor infiltration and modification of the TME By altering the local immune landscape the investigators aim to enhance CAR T cell persistence and efficacy while reducing the likelihood of tumor escape
By leveraging these two innovative strategies the investigators aim to achieve improved clinical outcomes in terms of both safety and efficacy The investigators hypothesize that the inclusion of immune microenvironment-activating elements will enhance the activation of not only CAR T cells but also the broader immune system creating a more hostile environment for tumor cells Furthermore direct tumor delivery of CAR T cells may increase their local concentration and activity reducing the tumor burden more effectively Through this optimized approach the investigators hope to provide a more potent and durable therapeutic option for patients with GPC3-positive hepatocellular carcinoma addressing the limitations encountered in previous trials
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None